Sun Pharma shares fall over 2% after US drug pricing deal
- Sun Pharma shares fell over 2% after the company agreed to lower US drug prices.
- The drugmaker will offer Most Favored Nation pricing to US state Medicaid programmes and future innovative drugs.
- The US will delay Section 232 tariffs on Sun Pharma’s innovative medicines for more than two years.
- The US accounts for about 27% of Sun Pharma’s global revenue, making the tariff relief significant.
Source: moneycontrol.com
Get 100 stories a day on the app
Read, watch & listen · Free on iOS & Android
